Hisamitsu Pharmaceutical Co. Inc. announced consolidated and non consolidated earnings results for the third quarter ended November 30, 2013. For the period, the company reported sales of JPY 115,129 million compared to JPY 107,357 million a year ago. Operating profits were JPY 18,487 million compared to JPY 20,773 million for the same period a year ago. Net profit before tax was JPY 30,554 million 25,589 million a year ago. Net profit was JPY 19,188 million compared to JPY 15,021 million a year ago.

For the period, on a non- consolidated basis, the company reported sales of JPY 95,335 million compared to JPY 92,447 million a year ago. Operating profits were JPY 23,761 million compared to JPY 23,141 million for the same period a year ago. Pretax profits were JPY 29,755 million 23,438 million a year ago. Net profit was JPY 19,088 million compared to JPY 14,091 million a year ago.

The company provided consolidated and non consolidated earnings guidance for full year of 2014. For the year, on consolidated basis, the company expects net profits of JPY 20,600 million, sales of JPY 151,500 million, operating profits of JPY 20,300 million, pre-tax profits of JPY 32,700 million and Capex of JPY 7,000 million. Depreciation expected to be JPY 5,200 million, goodwill amortization expected to be JPY 1,800 million and Amortization of stocks of subsidiaries and affiliate expected to be JPY 3,400 million.

For the year, on non consolidated basis, the company expects net profits of JPY 22,000 million, sales of JPY 125,500 million, operating profits of JPY 29,000 million; pre-tax profits of JPY 34,700 million and Capex of JPY 4,500 million. Depreciation expected to be JPY 3,100 million, goodwill amortization expected to be JPY 1,000 million.